301 related articles for article (PubMed ID: 23368770)
1. Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairment.
Lu J; Pontré B; Pickup S; Choong SY; Li M; Xu H; Gamble GD; Phillips AR; Cowan BR; Young AA; Cooper GJ
Cardiovasc Diabetol; 2013 Jan; 12():28. PubMed ID: 23368770
[TBL] [Abstract][Full Text] [Related]
2. Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats.
Zhang L; Ward ML; Phillips AR; Zhang S; Kennedy J; Barry B; Cannell MB; Cooper GJ
Cardiovasc Diabetol; 2013 Aug; 12():123. PubMed ID: 23981320
[TBL] [Abstract][Full Text] [Related]
3. Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments.
Lu J; Gong D; Choong SY; Xu H; Chan YK; Chen X; Fitzpatrick S; Glyn-Jones S; Zhang S; Nakamura T; Ruggiero K; Obolonkin V; Poppitt SD; Phillips AR; Cooper GJ
Diabetologia; 2010 Jun; 53(6):1217-26. PubMed ID: 20221822
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.
Cooper GJ
Drugs; 2011 Jul; 71(10):1281-320. PubMed ID: 21770477
[TBL] [Abstract][Full Text] [Related]
5. Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelation.
Zhang S; Liu H; Amarsingh GV; Cheung CC; Hogl S; Narayanan U; Zhang L; McHarg S; Xu J; Gong D; Kennedy J; Barry B; Choong YS; Phillips AR; Cooper GJ
Cardiovasc Diabetol; 2014 Jun; 13():100. PubMed ID: 24927960
[TBL] [Abstract][Full Text] [Related]
6. A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes.
Gong D; Lu J; Chen X; Reddy S; Crossman DJ; Glyn-Jones S; Choong YS; Kennedy J; Barry B; Zhang S; Chan YK; Ruggiero K; Phillips AR; Cooper GJ
Diabetologia; 2008 Sep; 51(9):1741-51. PubMed ID: 18636238
[TBL] [Abstract][Full Text] [Related]
7. Low-dose copper infusion into the coronary circulation induces acute heart failure in diabetic rats: New mechanism of heart disease.
Cheung CC; Soon CY; Chuang CL; Phillips AR; Zhang S; Cooper GJ
Biochem Pharmacol; 2015 Sep; 97(1):62-76. PubMed ID: 26208785
[TBL] [Abstract][Full Text] [Related]
8. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.
Cooper GJ; Young AA; Gamble GD; Occleshaw CJ; Dissanayake AM; Cowan BR; Brunton DH; Baker JR; Phillips AR; Frampton CM; Poppitt SD; Doughty RN
Diabetologia; 2009 Apr; 52(4):715-22. PubMed ID: 19172243
[TBL] [Abstract][Full Text] [Related]
9. Regeneration of the heart in diabetes by selective copper chelation.
Cooper GJ; Phillips AR; Choong SY; Leonard BL; Crossman DJ; Brunton DH; Saafi 'L; Dissanayake AM; Cowan BR; Young AA; Occleshaw CJ; Chan YK; Leahy FE; Keogh GF; Gamble GD; Allen GR; Pope AJ; Boyd PD; Poppitt SD; Borg TK; Doughty RN; Baker JR
Diabetes; 2004 Sep; 53(9):2501-8. PubMed ID: 15331567
[TBL] [Abstract][Full Text] [Related]
10. The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat.
Baynes JW; Murray DB
Exp Diabetes Res; 2009; 2009():696378. PubMed ID: 19390595
[TBL] [Abstract][Full Text] [Related]
11. Selective divalent copper chelation for the treatment of diabetes mellitus.
Cooper GJ
Curr Med Chem; 2012; 19(17):2828-60. PubMed ID: 22455587
[TBL] [Abstract][Full Text] [Related]
12. Effects of chelator treatment on aorta and corpus cavernosum from diabetic rats.
Keegan A; Cotter MA; Cameron NE
Free Radic Biol Med; 1999 Sep; 27(5-6):536-43. PubMed ID: 10490273
[TBL] [Abstract][Full Text] [Related]
13. Effects of trientine, a metal chelator, on defective endothelium-dependent relaxation in the mesenteric vasculature of diabetic rats.
Inkster ME; Cotter MA; Cameron NE
Free Radic Res; 2002 Oct; 36(10):1091-9. PubMed ID: 12516881
[TBL] [Abstract][Full Text] [Related]
14. Copper chelation in patients with hypertrophic cardiomyopathy.
Reid A; Miller C; Farrant JP; Polturi R; Clark D; Ray S; Cooper G; Schmitt M
Open Heart; 2022 Feb; 9(1):. PubMed ID: 35169044
[TBL] [Abstract][Full Text] [Related]
15. Molecular changes evoked by triethylenetetramine treatment in the extracellular matrix of the heart and aorta in diabetic rats.
Gong D; Lu J; Chen X; Choong SY; Zhang S; Chan YK; Glyn-Jones S; Gamble GD; Phillips AR; Cooper GJ
Mol Pharmacol; 2006 Dec; 70(6):2045-51. PubMed ID: 16973718
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of trientine and flaxseed oil on oxidative stress, serum lipids and heart structure in diabetic rats.
Rezaei A; Heidarian E
Indian J Exp Biol; 2013 Aug; 51(8):646-52. PubMed ID: 24228388
[TBL] [Abstract][Full Text] [Related]
17. Diabetes-induced alterations in tissue collagen and carboxymethyllysine in rat kidneys: Association with increased collagen-degrading proteinases and amelioration by Cu(II)-selective chelation.
Brings S; Zhang S; Choong YS; Hogl S; Middleditch M; Kamalov M; Brimble MA; Gong D; Cooper GJ
Biochim Biophys Acta; 2015 Aug; 1852(8):1610-8. PubMed ID: 25900786
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy.
Farrant J; Dodd S; Vaughan C; Reid A; Schmitt M; Garratt C; Akhtar M; Mahmod M; Neubauer S; Cooper RM; Prasad SK; Singh A; Valkovič L; Raman B; Ashkir Z; Clayton D; Baroja O; Duran B; Spowart C; Bedson E; Naish JH; Harrington C; Miller CA;
Heart; 2023 Jul; 109(15):1175-1182. PubMed ID: 37137675
[TBL] [Abstract][Full Text] [Related]
19. Trientine and renin-angiotensin system blockade ameliorate progression of glomerular morphology in hypertensive experimental diabetic nephropathy.
Moya-Olano L; Milne HM; Robinson JM; Hill JV; Frampton CM; Abbott HF; Turner R; Kettle AJ; Endre ZH
Pathol Int; 2011 Nov; 61(11):652-61. PubMed ID: 22029676
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
